BACKGROUND: The heptavalent pneumococcal CRM197 conjugate vaccine (PCV-7) has been incompletely studied in very-low-birth-weight (< or =1500 g) infants. OBJECTIVE: To assess PCV-7 immunogenicity in very-low-birth-weight, premature infants. We hypothesized that the frequency of postvaccine antibody concentrations > or =0.15 microg/mL would vary directly with birth weight. METHODS: This was a multicenter observational study. Infants 401 to 1500 g birth weight and <32 0/7 weeks gestation, stratified by birth weight, were enrolled from 9 National Institute of Child Health and Human Development Neonatal Research Network centers. Infants received PCV-7 at 2, 4, and 6 months after birth and had blood drawn 4 to 6 weeks following the third dose. Antibodies against the 7 vaccine serotypes were measured by enzyme-linked immunosorbent assay. RESULTS: Of 369 enrolled infants, 244 completed their primary vaccine series by 8 months and had serum obtained. Subjects were 27.8 +/- 2.2 (mean +/- standard deviation) weeks gestation and 1008 +/- 282 g birth weight. Twenty-six percent had bronchopulmonary dysplasia and 16% had received postnatal glucocorticoids. Infants 1001 to 1500 g birth weight were more likely than those 401 to 1000 g to achieve antibody concentrations > or =0.15 microg/mL against the least 2 immunogenic serotypes (6B: 96% vs. 85%, P = 0.003 and 23F: 97% vs. 88%, P = 0.009). In multiple logistic regression analysis, lower birth weight, postnatal glucocorticoid use, lower weight at blood draw, and Caucasian race were each independently associated with antibody concentrations <0.35 microg/mL against serotypes 6B and/or 23F. CONCLUSIONS: When compared with larger premature infants, infants weighing < or =1000 g at birth have similar antibody responses to most, but not all, PCV-7 vaccine serotypes.
BACKGROUND: The heptavalent pneumococcal CRM197 conjugate vaccine (PCV-7) has been incompletely studied in very-low-birth-weight (< or =1500 g) infants. OBJECTIVE: To assess PCV-7 immunogenicity in very-low-birth-weight, premature infants. We hypothesized that the frequency of postvaccine antibody concentrations > or =0.15 microg/mL would vary directly with birth weight. METHODS: This was a multicenter observational study. Infants 401 to 1500 g birth weight and <32 0/7 weeks gestation, stratified by birth weight, were enrolled from 9 National Institute of Child Health and Human Development Neonatal Research Network centers. Infants received PCV-7 at 2, 4, and 6 months after birth and had blood drawn 4 to 6 weeks following the third dose. Antibodies against the 7 vaccine serotypes were measured by enzyme-linked immunosorbent assay. RESULTS: Of 369 enrolled infants, 244 completed their primary vaccine series by 8 months and had serum obtained. Subjects were 27.8 +/- 2.2 (mean +/- standard deviation) weeks gestation and 1008 +/- 282 g birth weight. Twenty-six percent had bronchopulmonary dysplasia and 16% had received postnatal glucocorticoids. Infants 1001 to 1500 g birth weight were more likely than those 401 to 1000 g to achieve antibody concentrations > or =0.15 microg/mL against the least 2 immunogenic serotypes (6B: 96% vs. 85%, P = 0.003 and 23F: 97% vs. 88%, P = 0.009). In multiple logistic regression analysis, lower birth weight, postnatal glucocorticoid use, lower weight at blood draw, and Caucasian race were each independently associated with antibody concentrations <0.35 microg/mL against serotypes 6B and/or 23F. CONCLUSIONS: When compared with larger premature infants, infants weighing < or =1000 g at birth have similar antibody responses to most, but not all, PCV-7 vaccine serotypes.
Authors: Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm Journal: Clin Diagn Lab Immunol Date: 2003-07
Authors: Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian Journal: Vaccine Date: 2003-07-04 Impact factor: 3.641
Authors: S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards Journal: Pediatr Infect Dis J Date: 2000-03 Impact factor: 2.129
Authors: Henry Shinefield; Steven Black; Paula Ray; Bruce Fireman; Joan Schwalbe; Edwin Lewis Journal: Pediatr Infect Dis J Date: 2002-03 Impact factor: 2.129
Authors: Jens U Ruggeberg; Clare Collins; Paul Clarke; Nik Johnson; Ruchi Sinha; Neil Everest; John Chang; Elaine Stanford; Paul Balmer; Ray Borrow; Sarah Martin; Michael J Robinson; E Richard Moxon; Andrew J Pollard; Paul T Heath Journal: Vaccine Date: 2006-08-04 Impact factor: 3.641
Authors: Carl T D'Angio; Theresa E Murray; Lei Li; Roy J Heyne; T Michael O'Shea; Robert L Schelonka; Seetha Shankaran; Shahnaz Duara; Ronald N Goldberg; Barbara J Stoll; David K Stevenson; Betty R Vohr; Dale L Phelps; Waldemar A Carlo; Michael E Pichichero; Abhik Das; Rosemary D Higgins Journal: Pediatr Infect Dis J Date: 2013-12 Impact factor: 2.129
Authors: Jocelyn Y Ang; Jorge L Lua; Basim I Asmar; Seetha Shankaran; Roy J Heyne; Robert L Schelonka; Abhik Das; Lei Li; Delois M Jackson; Rosemary D Higgins; Carl T D'Angio Journal: Arch Pediatr Adolesc Med Date: 2010-12
Authors: Theresa J Ochoa; Alonso Zea-Vera; Rossana Bautista; Carmen Davila; José Antonio Salazar; Carlos Bazán; Luis López; Lucie Ecker Journal: Vaccine Date: 2014-11-21 Impact factor: 3.641
Authors: J L Wynn; L Li; C M Cotten; D L Phelps; S Shankaran; R N Goldberg; W A Carlo; K Van Meurs; A Das; B R Vohr; R D Higgins; B J Stoll; C T D'Angio Journal: J Perinatol Date: 2013-01-31 Impact factor: 2.521